Clinical trials: HIV Antibodies
HIV Infections, HIV Seronegativity
A Study of GENEVAX-HIV, a Possible Vaccine
The purpose of this study is to see if it is safe to give GENEVAX-HIV, a potential HIV vaccine, to HIV-negative volunteers. The study also compares the effects of GENEVAX-HIV injected into the muscle to the effects of the drug…
- Trial name
- NCT00002232
- Testing
- APL 400-003
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Wyeth-Lederle Vaccines
HIV, Human Immunodeficiency Virus
An Extension of Protocol PRO 140_CD01 Study
This is an extension of Protocol PRO 140_CD 01 to further evaluate the long-term suppression of HIV-1 replication following substitution of stable combination antiretroviral therapy with a PRO 140 (Monoclonal CCR5 antibody)…
- Trial name
- NCT02355184
- Testing
- PRO 140 350mg weekly subcutaneous (SC) injection.
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- CytoDyn, Inc.
HIV-1 Infection
Study to Assess Safety and Activity of Combination Therapy of VRC07-523LS and Vorinostat on HIV-infected Persons
Adult participants (18-64 years old) with HIV-1 Infection on ART with a CD4 T cell count ≥ 350 cells/mm3 and viral suppression for ≥ 24 months will be enrolled on this study.
- Trial name
- NCT03803605
- Testing
- VRC07-523LS, Vorinostat (VOR)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of North Carolina, Chapel Hill
HIV Infections, Varicella-zoster Virus
The Immunogenicity of Varicella-zoster Virus Vaccine in HIV-infected Children
To study about the immunogenicity, safety and efficacy of varicella-zoster virus vaccine in HIV-infected children.
- Trial name
- NCT01138215
- Testing
- VZV vaccination
- Where
- Thailand
- Volunteers
- 60 people
- Sponsor
- The HIV Netherlands Australia Thailand Research Collaboration
HIV Infections
Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults
Antibodies are natural proteins that the body makes to fight infections. Antibodies can also be manufactured like a drug and infused or injected into the body to prevent or treat a disease.
- Trial name
- NCT02165267
- Testing
- VRC01
- Where
- 6 sites in United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of the Monoclonal Antibody PGT121.414.LS Administered Alone and in Combination With VRC07-523LS Via Intravenous or Subcutaneous Infusions in Healthy, HIV-uninfected Adult Participants
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of the monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS via intravenous or…
- Trial name
- NCT04212091
- Testing
- PGT121.414.LS, VRC07-523LS
- Where
- 5 sites in United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1-infection, SARS-CoV Infection
SARS-CoV-2 (COVID-19) Antibody PrevalencE in an Adult London HIV Cohort
Prospective, observational SARS-CoV2 serological surveillance single London HIV outpatient center study using NHS participants
- Conditions
- HIV-1-infection, SARS-CoV Infection, Covid19
- Trial name
- SCAPE-HIV (NCT05067400)
- Where
- United Kingdom
- Volunteers
- 615 people
- Sponsor
- Royal Free Hospital NHS Foundation Trust
HIV Infections
Evaluating a Combination of Immune-based Therapies to Achieve a Remission of HIV Infection
A phase I/IIa, multinational, multicentric (IDIBAPS, IRSICAIXA, AARHUS, VUB, APHP), randomised, balanced by centre (to include participants from the 4 arms), open-label, controlled clinical trial.
- Trial name
- HIVACAR (NCT03619278)
- Testing
- HIVACAR
- Sponsor
- Judit Pich
HIV-1-infection
Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIV
This study is designed to evaluate the safety and efficacy of lefitolimod and 3BNC117/10-1074 in HIV-1-infected individuals on ART and during ATI as intervention to reduce the HIV-1 reservoir
- Trial name
- TITAN (NCT03837756)
- Testing
- Saline, Lefitolimod, 3BNC117 and 10-1074
- Where
- 8 sites in United States, Australia and 2 more
- Volunteers
- 47 people
- Sponsor
- University of Aarhus
Acquired Immunodeficiency Syndrome, Blood Transfusion
Effectiveness of AIDS Antibody Screening
To determine the effectiveness of efforts to eliminate the human immunodeficiency virus (HIV) from whole blood and blood components in the blood supply.
- Conditions
- Acquired Immunodeficiency Syndrome, Blood Transfusion, HIV Infections
- Trial name
- NCT00005303
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
To Assess Extended Safety and Tolerability of Subcutaneous CAP256V2LS and VRC07-523LS Monoclonal Antibodies in HIV-negative Women
A Phase II Trial to Assess Extended Safety and Tolerability of Subcutaneous CAP256V2LS and VRC07-523LS in HIV- Negative Women
A double blinded, Randomized, Placebo- controlled phase II trial to assess extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS in HIV- negative women
- Trial name
- CAPRISA 012C (NCT07810062)
- Testing
- Broad band monoclonal antibodies named as CAP256V2LS and VRC07- 523LS
- Where
- Zambia
- Volunteers
- 990 people, healthy volunteers welcome
- Sponsor
- Centre for Infectious Disease Research in Zambia
HIV Infections
A Study of Anti-HIV Monoclonal Antibody KD-247
The purpose of this study is to evaluate the safety and tolerability of 3 infusions of KD-247 over 2 weeks in HIV-1 seropositive individuals; to determine the pharmacokinetic parameters of KD-247 when administered as above; and…
- Trial name
- NCT00917813
- Testing
- KD-247, Physiological saline
- Where
- 15 sites in United States
- Volunteers
- 27 people
- Sponsor
- The Chemo-Sero-Therapeutic Research Institute
HIV/AIDS and Infections
A Randomised Placebo Controlled Trial of ART Plus Dual Long-acting HIV-specific Broadly Neutralising Antibodies (bNAbs).
RIO is a placebo-controlled double-blinded two arm prospective phase II randomised controlled trial . This study will test the use of broadly neutralising antibodies (bNAbs) in participants with treated primary HIV infection…
- Trial name
- RIO (NCT04319367)
- Testing
- Investigational Medicinal Product
- Where
- 12 sites in Denmark, United Kingdom
- Volunteers
- 72 people
- Sponsor
- Imperial College London
HIV Infections
Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men
The purpose of this study is to determine the safety and efficacy of a VRC DNA/rAd5 vaccine regimen in healthy, circumcised men and male-to-female (MTF) transgender persons who have sex with men.
- Trial name
- NCT00865566
- Testing
- DNA plasmid vaccine, Recombinant adenoviral serotype 5 (rAD5) vector vaccine
- Where
- 22 sites in United States
- Volunteers
- 2,504 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Clinical Trial of PGDM1400 and PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-infected and HIV-uninfected Adults
This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and anti-viral efficacy of the PGDM1400 and PGT121 and VRC07-523LS mAbs for HIV prevention and therapy.
- Trial name
- NCT03205917
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- International AIDS Vaccine Initiative
HIV Infection, Syphilis Infection
Multiplo Tp/HIV Self-Test
To help reach the undiagnosed living with HIV and/or syphilis in Canada, self-tests for HIV and Syphilis may have substantial utility for increased identification of infected individuals through their relative ease of use and…
- Trial name
- NCT06716450
- Testing
- Multiplo TP/HIV Antibody Test
- Where
- 3 sites in Canada
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Unity Health Toronto
HIV
A Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRCHIVMAB0115-00-AB (VRC01.23LS), Administered Intravenously or Subcutaneously to Healthy Adults
Background: HIV causes AIDS, a serious disease that can lead to fatal infections. HIV infection can be controlled but not cured, nor is there a vaccine to prevent it.
- Trial name
- NCT05627258
- Testing
- VRC-HIVMAB0115-00-AB
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hiv, Syphilis
Validation of Self Testing Using the INSTI Multiplex HIV1/2 Syphilis Antibody Test
This study aims to validate the percent agreement of the INSTI Multiplex Human Immunodeficiency (HIV) 1/2 syphilis antibody (Ab) test (INSTI POCT) when used as a self-test by patients compared to conventional serologic testing.
- Trial name
- NCT06953024
- Testing
- INSTI HIV/syphilis Point of Care Self-Test Administration
- Where
- Canada
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Nova Scotia Health Authority
HIV Infections
A Phase I Safety and Immunogenicity Trial of HIV-1 gp120 C4-V3 Hybrid Polyvalent Peptide Immunogen Mixed in Mineral Oil Containing Mannose Mono-Oleate (IFA)
To evaluate the safety of HIV-1 gp120 C4-V3 hybrid polyvalent peptide immunogen (C4-V3 peptides) formulated in mineral oil containing mannose mono-oleate (IFA) in HIV-1 uninfected volunteers.
- Trial name
- NCT00000886
- Testing
- HIV-1 C4-V3 Polyvalent Peptide Vaccine
- Where
- 3 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19, COVID-19 Vaccines
COVID-19 Quantitative Antibody Titers & Booster Vaccinations
This is an observational study aiming at describing COVID-19 vaccination outcomes among HIV-positive and HIV-negative individuals, using electronic health records to observe their usual clinical care.
- Conditions
- COVID-19, COVID-19 Vaccines, Immunogenicity, Vaccine
- Trial name
- NCT05104359
- Testing
- Observational
- Where
- United States
- Volunteers
- 825 people
- Sponsor
- Epividian